Published August 17, 2018
| Version v1
Journal article
Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit
Contributors
Others:
- Centre de Recherches en Cancérologie de Toulouse (CRCT) ; Université Toulouse III - Paul Sabatier (UT3) ; Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037) ; Université Toulouse III - Paul Sabatier (UT3) ; Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
- Laboratoire Interdisciplinaire Récits, Cultures et Sociétés (LIRCES) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS)-Université Côte d'Azur (UniCA)
- Institut Claudius Regaud (ICR)
- Department of Thoracic Oncology, Toulouse University Hospital
- Université Toulouse III - Paul Sabatier (UT3) ; Université de Toulouse (UT)
Description
Hydration is needed before and after cisplatin infusion for reducing the risk of nephrotoxicity. Even though there is no standard regimen, patients receive mostly intravenous hydration before and after cisplatin leading hospitalization during at least one night. Since the feasibility has been published, oral hydration after cisplatin was implemented in our practice. The safety of this new way of hydration needs to be assessed in clinical practice.
Abstract
International audienceAdditional details
Identifiers
- URL
- https://hal.science/hal-04970347
- URN
- urn:oai:HAL:hal-04970347v1
Origin repository
- Origin repository
- UNICA